home / stock / arvn / arvn news

ARVN News and Press, Arvinas Inc. From 02/20/24

Stock Information
Company Name: Arvinas Inc.
Stock Symbol: ARVN
Market: NASDAQ
Website: arvinas.com
Menu
ARVN ARVN Quote ARVN Short ARVN News ARVN Articles ARVN Message Board
Get ARVN Alerts

News, Short Squeeze, Breakout and More Instantly...
ARVN - Arvinas Announces Chief Financial Officer Transition

- Sean Cassidy leaving Arvinas as of February 29, 2024 - - Randy Teel, Ph.D. to assume the role of interim Chief Financial Officer - NEW HAVEN, Conn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology company creating a new class of dru...
ARVN - Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease

– ARV-102 is a novel oral PROTAC® protein degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2 (LRRK2) – – The Phase 1 trial of ARV-102 will evaluate safety, tolerability, pharmacokinetics, a...

ARVN - Citi downgrades Arvinas to neutral, cites valuation

2024-02-14 15:55:46 ET More on Arvinas Arvinas: Positive Breast Cancer Data Leads To Other Developments Arvinas: Protein Degradation Pioneer Presents An Intriguing Speculative Buy Opportunity Pfizer, Arvinas' breast cancer therapy gets FDA fast track status A...

ARVN - Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer

BOSTON, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced that the first patient has been dosed in its Phase 1b/2 clinical trial evaluating the combination of samuracicl...
ARVN - Arvinas Inc. (NASDAQ: ARVN) Climbs to New 52-Week High

Shares of Arvinas, Inc. (NASDAQ: ARVN) traded at a new 52-week high today and are currently trading at $48.13. So far today, approximately 40,727 shares have been exchanged, as compared to an average 30-day volume of 573.77k shares. Arvinas, Inc., a clinical-stage biopharmaceutical company, e...

ARVN - Arvinas stock rises on fast track status for breast cancer candidate with Pfizer

2024-02-06 07:03:50 ET More on Arvinas, Pfizer, etc. Pfizer: Simply Too Cheap To Ignore Pfizer Is Down 54% From Highs, Now Yields 6.1% Pfizer: Reviewing Q4 Earnings, FY24 Guidance - Why I Disagree With The Market Pharma giants turn to China in search of targe...

ARVN - Arvinas and Pfizer's Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer

-- Vepdegestrant is an investigational PROteolysis Targeting Chimera (PROTAC ® ) protein degrader designed to target and degrade the estrogen receptor (ER) protein -- NEW HAVEN, Conn. and NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE...
ARVN - Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference

NEW HAVEN, Conn., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ron Peck, M.D., Chief Medical Officer, and Randy Teel, Ph.D., Senior Vice President, C...

ARVN - Arvinas draws Buy at Goldman Sachs on breast cancer therapy

2024-02-01 15:42:17 ET More on Arvinas Arvinas: Positive Breast Cancer Data Leads To Other Developments Arvinas: Protein Degradation Pioneer Presents An Intriguing Speculative Buy Opportunity Wells Fargo upgrades Arvinas to overweight ahead of Phase 3 data readout ...

ARVN - AGN, CHRW and KLIC are among after hour movers

2024-01-31 17:03:58 ET Gainers: Nextracker  ( NXT ) +15% . Align Technology ( ALGN ) +11% . EZCORP ( EZPW ) +9% . Protagonist Therapeutics ( PTGX ) +8% . Cimpress ( CMPR ) +8% . Losers: MaxLinear ( MXL ) -8% ...
Previous 10 Next 10